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Background 
Shigellosis is an acute intestinal disease caused by infection by bacteria of the species Shigella or 
enterhemorrhagic Escherichia coli (EHEC), which contains a potent toxin called Shiga-toxin. Shigellosis 
affects over 150 million individuals world-wide each year, over one million of which result in death. The 
most severely affected subset of the population is children in developing countries. This disease is 
transmitted via a fecal-oral route. Clinical manifestations include mild to severe diarrhea, abdominal 
cramping, and fever, often leading to malnutrition and dehydration. Shigella and Shiga toxin-containing 
bacteria have developed multiple drug resistance, leaving the condition without treatment options. 
Citrobacter rodentium (CR), a bacterium that is genotypically and phenotypically similar to EHEC, is used 
to model Shigellosis in mice to study this disease. 
Materials 
Mice were infected with CR containing Shiga-toxin and either did or did not receive treatment with (1) 
streptomycin or (2) valproic acid, manganese, and glycine. Treatment efficacy was assessed by 
gastrointestinal transit, mouse weight, and colonic inflammation. 
Results 
Conventional mice showed significant weight loss, colonic inflammation, and decreased cecum weight in 
relation to mice receiving continual strep treatment. Additionally, treatment with VPA and Mn reduced 
the inflammatory response of CR infection.  
Conclusion 
The increased diseased response of mice receiving no antibiotic treatment in relation to those receiving 
strep treatment shows that bacterial competition drives pathogenesis. We propose that VPA and Mn 
treatment mitigate this EHEC virulence by acting as a histone deacetylase inhibitor to induce 
transcriptional repression of Gb3 receptors and suppressing expression of stx carrier protein GPP130, 
thus providing the first available treatment to EHEC-induced Shigallosis.  
 
 
 
